Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication
about
Cognitive dysfunction and work productivity in major depressive disorder.Sleep complaints in adolescent depression: one year naturalistic follow-up studyThe role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression.Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus.Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysisMajor depressive disorder: mechanism-based prescribing for personalized medicineInsomnia associated with depressive disorder: primary, secondary, or mixed?IL-1β and BDNF are associated with improvement in hypersomnia but not insomnia following exercise in major depressive disorder.Twelve-month, prospective, open-label study of repetitive transcranial magnetic stimulation for major depressive disorder in partial remission.Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trialsThe complex role of sleep in adolescent depression.Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-α treatment.Improvements in Depression and Changes in Fatigue: Results from the SLAM DUNC Depression Treatment Trial.Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder.Concise set of files for smooth return to work in employees with mental disorders.The impact of residual symptoms on relapse and quality of life among Thai depressive patients.Major depressive disorder and sleep disturbance in patients with chronic pain.Clinical relevance of fatigue as a residual symptom in major depressive disorder.Restoration of positive mood states in major depression as a potential drug development target.Antidepressant drug development: Focus on triple monoamine reuptake inhibition.Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials.Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression.Insomnia as a Precipitating Factor in New Onset Mental Illness: a Systematic Review of Recent Findings.Changes in depression subtypes for women during treatment with citalopram: a latent transition analysis.Effectiveness of Benzodiazepine Receptor Agonists in the Treatment of Insomnia: An Examination of Response and Remission Rates.Effects of Antidepressants on Sleep.Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression.Hippocampal-Dependent Antidepressant Action of the H3 Receptor Antagonist Clobenpropit in a Rat Model of Depression.Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome.Does exercise improve self-reported sleep quality in non-remitted major depressive disorder?Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice.Italian neurologists' perception on cognitive symptoms in major depressive disorder.Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis.Patient-centered assessment of cognitive symptoms of depression.An open-label study of adjunctive repetitive transcranial magnetic stimulation (rTMS) for partial remission in major depressive disorder.Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of RX-10100 (Serdaxin®) in subjects with major depressive disorder.Characteristics of Residual Symptoms in Korean Patients with Major Depressive Disorder: A Validation Study for the Korean Version of Depression Residual Symptom Scale.Depression and coronary heart disease.Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression.A Chinese chan-based mind-body intervention improves sleep on patients with depression: a randomized controlled trial.
P2860
Q30249792-4B5B0211-66C4-4A0F-A20C-C81758A3658CQ34334019-630C64AF-D432-4B87-BCA9-3ED589F7818EQ34335586-4F2A8935-BA64-4274-9A3C-991684C9F783Q34505291-AA2EEE7E-78B2-4B1E-B4EE-8F3770FF8A40Q34582365-D4E29348-6F0C-42C3-92FA-A3DA501574D9Q35284412-3DDE55CB-6C7E-4EFE-81E5-21DCCDB6845FQ35732296-F96FF9FB-8346-4E2D-BA23-432908A79D9EQ36043319-0469AE75-E1C9-4A8C-B642-5FDEC763C9F0Q36207106-8CF7A1AA-AD34-4140-A364-7FC4A6F2BC39Q36380157-E89C042C-2ED5-4F06-A303-8C1F4025CD06Q36709553-0D832EC0-7C51-482F-B539-6F325B54F831Q36775228-9C635A22-F986-4ED7-8AD7-81982246F88FQ36998562-A44011A3-8C87-4117-AA7B-0EB5B96D6799Q37309556-05D3A7CB-9DE9-4E24-A656-15D0B218C83EQ37364949-0E2BB6C7-DD03-4B6A-AF11-A7316FCB54F2Q37510121-2E23A143-BCB1-4A9A-9C39-08022B183A81Q37609818-33DFDAE0-F602-4D35-905A-2410E7CC6AADQ38151637-17BEF882-4CD5-4E20-ABB5-BC02062F8138Q38210460-88067F95-1825-4E5A-8088-695E6F3B69BEQ38260259-A2CC7036-1C24-4963-98AE-7CF45D93D480Q38391306-8E941C1A-9EEF-4B89-A768-15482691A415Q39328768-E8F4964A-7E22-468A-AFF0-7AE8E22D70ADQ39375201-A644CED5-E3F9-425D-8126-DE5C98A14FB9Q40071013-9F3217FD-CA8E-4C57-A2E5-ED6A9B41A992Q40264491-C301FBD2-FBB9-4CA7-84B9-2E09319344A5Q41310657-208B085A-4D07-449D-8AB9-A0A1FEAB569EQ41994846-A1328157-2237-4CC8-BF86-C4A18C1B7709Q42002128-D34F94FF-B406-4B24-8606-5E36E8922D19Q45937835-07E95E36-5EC4-4D39-8349-AF89021BAE1FQ46674667-3BD7C941-4736-4067-86ED-D1627BCF4C38Q47550351-65B4B714-468F-4F1F-A7A3-D4642EC7B4C5Q48056101-7611F5D8-6A8D-481C-9ECC-E31FA0DE5A54Q48057578-F6CCD70A-FD74-4252-B297-CC92C318EFEEQ48421933-AE639A1F-9452-4967-8FBA-C31E68B631AEQ48729844-67C140B8-2CCE-4449-91F2-F7A1AD4EC953Q48773640-6D99B38B-7397-4680-801A-6686882EF1ABQ53081881-082B05A2-471D-4E14-A025-14B72FE3CF29Q53131906-50BF97EA-D487-4CFD-95AF-45F050B8506CQ55132660-24B19100-3FC0-474D-BE7A-994F74F8A293Q55405881-A7EF22F8-914A-4113-AC86-D4B54D4C6223
P2860
Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Residual symptoms in depressed ...... t to antidepressant medication
@ast
Residual symptoms in depressed ...... t to antidepressant medication
@en
Residual symptoms in depressed ...... t to antidepressant medication
@nl
type
label
Residual symptoms in depressed ...... t to antidepressant medication
@ast
Residual symptoms in depressed ...... t to antidepressant medication
@en
Residual symptoms in depressed ...... t to antidepressant medication
@nl
prefLabel
Residual symptoms in depressed ...... t to antidepressant medication
@ast
Residual symptoms in depressed ...... t to antidepressant medication
@en
Residual symptoms in depressed ...... t to antidepressant medication
@nl
P2093
P2860
P1476
Residual symptoms in depressed ...... t to antidepressant medication
@en
P2093
Andrew A Nierenberg
David Morris
Diane Warden
Jonathan W Stewart
Madhukar H Trivedi
Mustafa M Husain
Shawn M McClintock
P2860
P304
P356
10.1097/JCP.0B013E31820EBD2C
P407
P577
2011-04-01T00:00:00Z